NASDAQ:BFRI Biofrontera (BFRI) Stock Price, News & Analysis → Move Your Money Before May 1 (From Stansberry Research) (Ad) Free BFRI Stock Alerts $1.65 -0.04 (-2.37%) (As of 02:39 PM ET) Add Compare Share Share Today's Range$1.60▼$1.7350-Day Range$0.75▼$2.3852-Week Range$0.61▼$13.42Volume19,743 shsAverage Volume631,019 shsMarket Capitalization$8.40 millionP/E RatioN/ADividend YieldN/APrice Target$18.00 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesOwnershipSEC FilingsShort InterestSocial Media Get Biofrontera alerts: Email Address Biofrontera MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside977.8% Upside$18.00 Price TargetShort InterestHealthy1.20% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews SentimentN/AInsider TradingN/AProj. Earnings GrowthGrowingFrom ($4.01) to ($0.19) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.1.78 out of 5 stars 3.5 Analyst's Opinion Consensus RatingBiofrontera has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 1 buy rating, no hold ratings, and no sell ratings.Amount of Analyst CoverageBiofrontera has received no research coverage in the past 90 days. Previous Next 3.0 Short Interest Percentage of Shares Shorted1.20% of the float of Biofrontera has been sold short.Short Interest Ratio / Days to CoverBiofrontera has a short interest ratio ("days to cover") of 0.1, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Biofrontera has recently increased by 26.44%, indicating that investor sentiment is decreasing significantly. Previous Next 0.0 Dividend Strength Dividend YieldBiofrontera does not currently pay a dividend.Dividend GrowthBiofrontera does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for BFRI. Previous Next 1.1 News and Social Media Coverage News SentimentBiofrontera has a news sentiment score of -1.00. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.33 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 1 news article for Biofrontera this week, compared to 1 article on an average week.Search Interest4 people have searched for BFRI on MarketBeat in the last 30 days. This is an increase of 300% compared to the previous 30 days.MarketBeat FollowsOnly 3 people have added Biofrontera to their MarketBeat watchlist in the last 30 days. This is a decrease of -25% compared to the previous 30 days. Previous Next 0.0 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Biofrontera insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 0.69% of the stock of Biofrontera is held by insiders.Percentage Held by InstitutionsOnly 10.08% of the stock of Biofrontera is held by institutions. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Biofrontera are expected to grow in the coming year, from ($4.01) to ($0.19) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Biofrontera is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Biofrontera is -0.11, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioBiofrontera has a P/B Ratio of 0.53. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities. Previous Next See Top Rated MarketRank™ Stocks Here Ad Stansberry ResearchMove Your Money Before May 22The SIX WORDS That Could Destroy America... And The Value of Your Savings. He predicted the dangerous rise of inflation... the death of the 60/40 portfolio... and now, this 40-year market veteran and retirement expert is stepping forward with a new must-see warning for every American. It involves the world's most powerful investors, central bankers, and America's most bitter geopolitical rivals. Here's where Dr. David Eifrig says to move your money immediately. About Biofrontera Stock (NASDAQ:BFRI)Biofrontera Inc., a biopharmaceutical company, engages in the commercialization of pharmaceutical products for the treatment of dermatological conditions in the United States. The company's products are used for the treatment of actinic keratoses, which are pre-cancerous skin lesions, as well as impetigo, a bacterial skin infection. It offers Ameluz, a prescription drug for use in combination with the RhodoLED lamp series, for photodynamic therapy for the lesion-directed and field-directed treatment of actinic keratosis of mild-to-moderate severity on the face and scalp. The company also provides Xepi, a topical non-fluorinated quinolone that inhibits bacterial growth for the treatment of impetigo. The company was incorporated in 2015 and is headquartered in Woburn, Massachusetts.Read More BFRI Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart BFRI Stock News HeadlinesMarch 24, 2024 | investorplace.com3 Mind-Blowing Stocks That Could Turn $1,000 Into $1 MillionMarch 20, 2024 | seekingalpha.comBiofrontera Inc. (BFRI) Q4 2023 Earnings Call TranscriptApril 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? March 19, 2024 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Q4 2023 Earnings Call TranscriptMarch 18, 2024 | msn.comBiofrontera GAAP EPS of $1.65 beats by $2.79, revenue of $10.6M misses by $1.21MFebruary 20, 2024 | msn.comBiofrontera stock soars on announcing private placement of up to $16MFebruary 20, 2024 | finance.yahoo.comBiofrontera Inc. Announces Restructuring of Supply Agreement with Biofrontera AGJanuary 31, 2024 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI): Is Breakeven Near?April 26, 2024 | Stansberry Research (Ad)Move Your Money Before May 1Did you know that the IRS has allegedly been using AI to spy on the bank accounts of American citizens? January 11, 2024 | msn.comBiofrontera sees 19% growth in prelim FY 2023 revenueNovember 22, 2023 | finance.yahoo.comBiofrontera Inc. (BFRI) Forms 'Hammer Chart Pattern': Time for Bottom Fishing?November 11, 2023 | finance.yahoo.comBiofrontera Inc. (NASDAQ:BFRI) Q3 2023 Earnings Call TranscriptNovember 11, 2023 | finance.yahoo.comBenign Growth For Biofrontera Inc. (NASDAQ:BFRI) Underpins Stock's 50% PlummetNovember 9, 2023 | finance.yahoo.comBiofrontera Inc. Reports Third Quarter 2023 Financial Results and Provides a Business UpdateNovember 9, 2023 | finance.yahoo.comBiofrontera Inc. (BFRI) Upgraded to Buy: Here's What You Should KnowNovember 3, 2023 | finance.yahoo.comBiofrontera Inc. to Report Third Quarter 2023 Financial Results on November 9 and Hold Conference Call on November 10October 31, 2023 | finance.yahoo.comBiofrontera Inc. Announces $4.5 Million Registered Direct Offering Priced At-the-market Under NASDAQ RulesOctober 21, 2023 | ca.finance.yahoo.comBiofrontera Inc. (BFRI) Stock Price, News, Quote & History - Yahoo FinanceOctober 10, 2023 | finanznachrichten.deBiofrontera Inc. Receives FDA Approval for New Formulation of AmeluzOctober 10, 2023 | finance.yahoo.comBiofrontera Inc. Receives FDA Approval for New Formulation of Ameluz(R)October 5, 2023 | finance.yahoo.comBiofrontera Inc. to Participate in the Roth MKM 2023 Healthcare Opportunities Conference and the 43rd Annual Fall Clinical Dermatology ConferenceSeptember 18, 2023 | msn.comAll You Need to Know About Biofrontera Inc. (BFRI) Rating Upgrade to BuyAugust 28, 2023 | finanznachrichten.deBiofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of AmeluzAugust 28, 2023 | finance.yahoo.comBiofrontera Inc. Announces Positive Results from Phase 1 Safety Study Evaluating Photodynamic Therapy with Three Tubes of Ameluz(R)August 10, 2023 | benzinga.comEarnings Outlook For BiofronteraAugust 4, 2023 | finance.yahoo.comBiofrontera Inc. to Report Second Quarter Financial Results on August 11, 2023July 13, 2023 | finance.yahoo.comBiofrontera Inc. Announces Preliminary Second Quarter Revenues are Up 26% to 31%See More Headlines Receive BFRI Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Biofrontera and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings3/15/2024Today4/26/2024Next Earnings (Estimated)5/10/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:BFRI CUSIPN/A CIK1858685 Webwww.biofrontera-us.com Phone781-245-1325FaxN/AEmployees83Year FoundedN/APrice Target and Rating Average Stock Price Target$18.00 High Stock Price Target$18.00 Low Stock Price Target$18.00 Potential Upside/Downside+977.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage1 Analysts Profitability EPS (Most Recent Fiscal Year)($15.82) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-20,130,000.00 Net Margins-59.09% Pretax Margin-59.04% Return on Equity-344.98% Return on Assets-72.85% Debt Debt-to-Equity RatioN/A Current Ratio1.28 Quick Ratio0.67 Sales & Book Value Annual Sales$34.07 million Price / Sales0.25 Cash FlowN/A Price / Cash FlowN/A Book Value$3.16 per share Price / Book0.53Miscellaneous Outstanding Shares5,090,000Free Float5,054,000Market Cap$8.50 million OptionableNo Data Beta0.83 Ten Starter Stocks For Beginners to Buy NowJust getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.Get This Free Report Key ExecutivesDr. Hermann Luebbert Ph.D. (Age 68)CEO, President & Executive Chairman Comp: $733.23kMr. Eugene Frederick Leffler III (Age 39)Chief Financial Officer Comp: $378.58kMs. Erica F. Gates CPAM.B.A., Senior Director of Finance & Principal Accounting OfficerMr. Jon Lyons M.B.A.Ph.D., Vice President of Scientific & Medical AffairsMs. Alycia TorresVice President of AdministrationMr. Daniel Hakansson J.D.General Counsel & Head of ComplianceMs. Samantha WiddicombeSenior Director of Strategic Accounts & CommunicationsMr. Mark BaldygaVice President of Sales & MarketingMore ExecutivesKey CompetitorsTFF PharmaceuticalsNASDAQ:TFFPASLAN PharmaceuticalsNASDAQ:ASLNBionomicsNASDAQ:BNOXLixte BiotechnologyNASDAQ:LIXTChemomab TherapeuticsNASDAQ:CMMBView All CompetitorsInstitutional OwnershipRosalind Advisors Inc.Bought 504,261 shares on 4/25/2024Ownership: 9.907%View All Institutional Transactions BFRI Stock Analysis - Frequently Asked Questions Should I buy or sell Biofrontera stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Biofrontera in the last year. There are currently 1 buy rating for the stock. The consensus among Wall Street research analysts is that investors should "buy" BFRI shares. View BFRI analyst ratings or view top-rated stocks. What is Biofrontera's stock price target for 2024? 1 Wall Street analysts have issued twelve-month price targets for Biofrontera's stock. Their BFRI share price targets range from $18.00 to $18.00. On average, they expect the company's share price to reach $18.00 in the next twelve months. This suggests a possible upside of 977.8% from the stock's current price. View analysts price targets for BFRI or view top-rated stocks among Wall Street analysts. How have BFRI shares performed in 2024? Biofrontera's stock was trading at $2.77 at the beginning of the year. Since then, BFRI shares have decreased by 39.7% and is now trading at $1.67. View the best growth stocks for 2024 here. Are investors shorting Biofrontera? Biofrontera saw a increase in short interest during the month of April. As of April 15th, there was short interest totaling 44,000 shares, an increase of 26.4% from the March 31st total of 34,800 shares. Based on an average trading volume of 759,100 shares, the short-interest ratio is presently 0.1 days. Approximately 1.2% of the company's shares are sold short. View Biofrontera's Short Interest. When is Biofrontera's next earnings date? The company is scheduled to release its next quarterly earnings announcement on Friday, May 10th 2024. View our BFRI earnings forecast. How were Biofrontera's earnings last quarter? Biofrontera Inc. (NASDAQ:BFRI) issued its quarterly earnings data on Friday, March, 15th. The company reported ($2.33) earnings per share (EPS) for the quarter. The business had revenue of $10.60 million for the quarter. Biofrontera had a negative net margin of 59.09% and a negative trailing twelve-month return on equity of 344.98%. When did Biofrontera's stock split? Biofrontera's stock reverse split on the morning of Wednesday, July 5th 2023. The 1-20 reverse split was announced on Wednesday, July 5th 2023. The number of shares owned by shareholders was adjusted after the market closes on Wednesday, July 5th 2023. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split. What guidance has Biofrontera issued on next quarter's earnings? Biofrontera issued an update on its FY 2023 earnings guidance on Tuesday, January, 30th. The company provided earnings per share (EPS) guidance of for the period. The company issued revenue guidance of $33.8 million-$34.3 million, compared to the consensus revenue estimate of $35.9 million. When did Biofrontera IPO? Biofrontera (BFRI) raised $19 million in an IPO on Friday, October 29th 2021. The company issued 3,100,000 shares at a price of $5.00-$7.00 per share. Roth Capital Partners and The Benchmark Company acted as the underwriters for the IPO. Who are Biofrontera's major shareholders? Biofrontera's stock is owned by a number of retail and institutional investors. Top institutional shareholders include Rosalind Advisors Inc. (9.91%). How do I buy shares of Biofrontera? Shares of BFRI stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:BFRI) was last updated on 4/26/2024 by MarketBeat.com Staff From Our PartnersThese AI trades triggered this morning (545% return)Prosper Trading AcademyThe Best AI Stock to Own in the World Today is Trading for Just $25Banyan Hill PublishingConflict In Israel Sends Gold Soaring ???? Here’s How To Get Your ShareColonial MetalsRed Alert: Your Money's Disappearance Act - Banks' Greed Unleashed!Priority GoldExposed: 10 CENT Crypto to Explode April 20th?True Market InsidersThe A.I. story nobody is telling you (Read ASAP)TradeSmithDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTrump is sounding the alarmPreserve Gold Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Biofrontera Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
